1. Home
  2. LOAN vs ENTX Comparison

LOAN vs ENTX Comparison

Compare LOAN & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Manhattan Bridge Capital Inc

LOAN

Manhattan Bridge Capital Inc

HOLD

Current Price

$4.41

Market Cap

49.5M

Sector

Real Estate

ML Signal

HOLD

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.01

Market Cap

47.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOAN
ENTX
Founded
1989
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.5M
47.2M
IPO Year
1999
2015

Fundamental Metrics

Financial Performance
Metric
LOAN
ENTX
Price
$4.41
$1.01
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
17.5K
164.0K
Earning Date
03-27-2026
03-27-2026
Dividend Yield
9.89%
N/A
EPS Growth
N/A
N/A
EPS
0.45
0.25
Revenue
$8,666,307.00
$42,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.47
N/A
P/E Ratio
$12.71
$6.28
Revenue Growth
N/A
N/A
52 Week Low
$4.13
$0.98
52 Week High
$6.05
$3.22

Technical Indicators

Market Signals
Indicator
LOAN
ENTX
Relative Strength Index (RSI) 53.02 38.24
Support Level $4.26 N/A
Resistance Level $4.45 $1.61
Average True Range (ATR) 0.11 0.17
MACD 0.02 -0.02
Stochastic Oscillator 76.08 13.64

Price Performance

Historical Comparison
LOAN
ENTX

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Share on Social Networks: